Valhalla hills capacity vs ordered trial#
Recently announced results from the PATHFINDER clinical trial showed adding the Galleri MCED test to standard of care screening more than doubled the number of cancers detected, and the test predicted where a cancer signal originated with 97% accuracy. Using advanced genomics and machine learning, the test also predicts the origin of the cancer signal, which enables targeted diagnostic evaluation. In a clinical study, the Galleri test demonstrated the ability to detect a shared signal across more than 50 types of cancers, over 45 of which lack recommended screening tests today.
“GRAIL’s early cancer detection test is a critical component in a comprehensive oncology offering and we’re thrilled to extend this benefit to Carrum members.”
“In developing Carrum’s comprehensive oncology offering we’ve carefully selected partners who share in our mission to tackle both the rising costs of cancer care and solutions that vastly improve the patient experience,” said Sach Jain, CEO and founder of Carrum Health. This product integration will enable employers who offer Carrum Health benefits to provide eligible employees the Galleri test as part of the comprehensive cancer care Carrum delivers. 13, 2022 - GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Carrum Health, the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered, value-based care platform, today announced a first-of-its-kind partnership to include the Galleri® multi-cancer early detection (MCED) test as part of Carrum Health’s oncology offering to self-insured employers. MENLO PARK, Calif., and SAN FRANCISCO, Oct. MCED Test Offered as Part of Comprehensive Value-Based Cancer Care to Improve Outcomes and Reduce Costs Through Carrum Health’s Network of Customers, Eligible Employees Will Have Access to GRAIL’s Galleri® Multi-Cancer Early Detection (MCED) Test
0 kommentar(er)
